Complex analysis of the personalized pharmacotherapy in the management of COVID-19 patients and suggestions for applications of predictive, preventive, and personalized medicine attitude

Abstract Aims Coronavirus disease 2019 (COVID-19) is rapidly spreading worldwide. Drug therapy is one of the major treatments, but contradictory results of clinical trials have been reported among different individuals. Furthermore, comprehensive analysis of personalized pharmacotherapy is still lacking. In this study, analyses were performed on 47 well-characterized COVID-19 drugs used in the personalized treatment of COVID-19. Methods Clinical trials with published results of drugs use for COVID-19 treatment were collected to evaluate drug efficacy. Drug-to-Drug Interactions (DDIs) were summarized and classified. Functional variations in actionable pharmacogenes were collected and systematically analysed. “Gene Score” and “Drug Score” were defined and calculated to systematically analyse ethnicity-based genetic differences, which are important for the safer use of COVID-19 drugs. Results Our results indicated that four antiviral agents (ritonavir, darunavir, daclatasvir and sofosbuvir) and three immune regulators (budesonide, colchicine and prednisone) as well as heparin and enalapril could generate the highest number of DDIs with common concomitantly utilized drugs. Eight drugs (ritonavir, daclatasvir, sofosbuvir, ribavirin, interferon alpha-2b, chloroquine, hydroxychloroquine (HCQ) and ceftriaxone had actionable pharmacogenomics (PGx) biomarkers among all ethnic groups. Fourteen drugs (ritonavir, daclatasvir, prednisone, dexamethasone, ribavirin, HCQ, ceftriaxone, zinc, interferon beta-1a, remdesivir, levofloxacin, lopinavir, human immunoglobulin G and losartan) showed significantly different pharmacogenomic characteristics in relation to the ethnic origin of the patient. Conclusion We recommend that particularly for patients with comorbidities to avoid serious DDIs, the predictive, preventive, and personalized medicine (PPPM, 3 PM) strategies have to be applied for COVID-19 treatment, and genetic tests should be performed for drugs with actionable pharmacogenes, especially in some ethnic groups with a higher frequency of functional variations, as our analysis showed. We also suggest that drugs associated with higher ethnic genetic differences should be given priority in future pharmacogenetic studies for COVID-19 management. To facilitate translation of our results into clinical practice, an approach conform with PPPM/3 PM principles was suggested. In summary, the proposed PPPM/3 PM attitude should be obligatory considered for the overall COVID-19 management.

Download Full-text

Inflammatory and metabolic profiles of patients with end-stage renal disease: potential strategy for predictive, preventive, and personalized medicine

10.21203/rs.3.rs-204650/v1 ◽

2021 ◽

Author(s):

Xiaoxin Ma ◽

Yongli Wang ◽

Hongyu Wu ◽

Fei Li ◽

Xiping Feng ◽

...

Keyword(s):

Personalized Medicine ◽

End Stage Renal Disease ◽

Healthy Controls ◽

Preventive And Personalized Medicine ◽

Hydroxyphenylacetic Acid ◽

Potential Strategy ◽

Stage Renal Disease ◽

End Stage ◽

Esrd Patients ◽

And Personalized Medicine

Abstract Objectives Few studies reported the periodontal disease-related metabolic profile of end-stage renal disease (ESRD) patients. The present study aimed to compare the inflammatory and metabolic differences between patients with ESRD and healthy controls, and to identify potential useful biomarkers for predictive, preventive, and personalized medicine (PPPM) in GCP and serum of ESRD patients.Methods Patients with ESRD (ESRD group; n = 52) and healthy controls (HC group; n = 44) were recruited. Clinical periodontal parameters were recorded. The differential metabolites in the GCF and serum were identified by liquid chromatography/mass spectrometry. Inflammatory markers including Interleukin-1β (IL-1β), Interleukin-6 (IL-6), Interleukin-8 (IL-8) and C-reactive protein (CRP) were also assessed. Results In ESRD group, IL-8 and CRP were significantly higher in GCF, whereas IL-6 and CRP were significantly higher in serum, compared with HC group (all P < 0.05). In the case of GCF, taurine levels were positively correlated with IL-8 levels in both groups (all P < 0.05). In the case of serum, L-phenylalanine and p-hydroxyphenylacetic acid levels were positively correlated with CRP levels in both groups (all P < 0.05). Significant positive correlation was observed between pseudouridine and IL-6 levels only in ESRD group. Conclusions IL-8 and CRP were potential inflammatory makers. Metabolites of taurine in GCF as well as L-phenylalanine and p-hydroxyphenylacetic acid in serum were possible biomarkers that correlated with inflammatory cytokine. All these biomarkers may consider as a potential strategy for the prediction, diagnosis, prognosis, and management of personalized periodontal therapy in the population with ESRD.

Download Full-text

Simultaneous Systematic Approach to Enable Predictive, Preventive and Personalized Medicine – Women Healthcare as a Case Study

Advances in Predictive, Preventive and Personalised Medicine - Healthcare Overview ◽

10.1007/978-94-007-4602-2_17 ◽

2012 ◽

pp. 313-331 ◽

Cited By ~ 2

Author(s):

Mira Marcus-Kalish ◽

Hamutal Meiri

Keyword(s):

Personalized Medicine ◽

Systematic Approach ◽

Preventive And Personalized Medicine ◽

And Personalized Medicine

Download Full-text

Identification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine

The EPMA Journal ◽

10.1007/s13167-020-00220-3 ◽

2020 ◽

Vol 11 (3) ◽

pp. 485-504 ◽

Cited By ~ 3

Author(s):

Na Li ◽

Xianquan Zhan

Keyword(s):

Lung Cancer ◽

Personalized Medicine ◽

Rna Modification ◽

Cancer Management ◽

Preventive And Personalized Medicine ◽

And Personalized Medicine

Download Full-text

Breast Cancer in Young Women: Status Quo and Advanced Disease Management by a Predictive, Preventive, and Personalized Approach

Cancers ◽

10.3390/cancers11111791 ◽

2019 ◽

Vol 11 (11) ◽

pp. 1791 ◽

Cited By ~ 8

Author(s):

Erik Kudela ◽

Marek Samec ◽

Peter Kubatka ◽

Marcela Nachajova ◽

Zuzana Laucekova ◽

...

Keyword(s):

Breast Cancer ◽

Personalized Medicine ◽

Disease Management ◽

Young Women ◽

Screening Tools ◽

Molecular Signature ◽

Young Females ◽

Preventive And Personalized Medicine ◽

Personalized Approach ◽

And Personalized Medicine

Why does healthcare of breast cancer (BC) patients, especially in a young population, matter and why are innovative strategies by predictive, preventive, and personalized medicine (PPPM) strongly recommended to replace current reactive medical approach in BC management? Permanent increase in annual numbers of new BC cases with particularly quick growth of premenopausal BC patients, an absence of clearly described risk factors for those patients, as well as established screening tools and programs represent important reasons to focus on BC in young women. Moreover, "young" BC cases are frequently "asymptomatic", difficult to diagnose, and to treat effectively on time. The objective of this article is to update the knowledge on BC in young females, its unique molecular signature, newest concepts in diagnostics and therapy, and to highlight the concepts of predictive, preventive, and personalized medicine with a well-acknowledged potential to advance the overall disease management.

Download Full-text